The observations of elevated serum IL-10 levels in SLE patients correlating with increased disease activity [13], [14], and promising findings of anti-IL-10 monoclonal antibody treatment in patients with SLE [15] support a pivotal role for IL-10 in the pathogenesis of SLE. This evidence concerns the gene IL10 and systemic lupus erythematosus.